Buy Curosurf 80 mg/mL poractant alfa

Curosurf 80 mg/mL is a suspension used for respiratory support in premature infants. This poractant alfa formulation aids in lung function and is administered via endotracheal route.

Strength

80 mg/mL

Pack Size

3 mL in 1 VIAL, GLASS (10122-510-03)

Manufacturer / TM Owner

Chiesi USA, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Curosurf 80 mg/mL is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition often occurs due to a lack of surfactant in the lungs, which is crucial for proper breathing. The suspension helps to improve lung function and reduce the need for mechanical ventilation. What is Curosurf used for? It is specifically designed to provide respiratory support in neonatal intensive care units.

Side Effects

Common effects of Curosurf 80 mg/mL may include improved lung compliance and reduced respiratory distress. It works by replacing the natural surfactant in the lungs, which helps to keep the air sacs open and functioning properly. This can lead to easier breathing and better oxygenation for the infant.

Precautions & Warnings

Curosurf 80 mg/mL should be handled with care and administered by trained medical professionals. It is important to follow proper storage and handling guidelines to maintain the integrity of the suspension. Always consult healthcare providers for specific precautions and contraindications.

Avoid Interactions

Curosurf 80 mg/mL may interact with other medications or treatments. It is important to inform healthcare providers about all current medications and treatments before administration. Specific interactions should be discussed with a healthcare professional to ensure safety and effectiveness.

References

Frequently Asked Questions

Curosurf 80 mg/mL is used to treat respiratory distress syndrome (RDS) in premature infants by providing respiratory support.

Curosurf is administered via the endotracheal route, directly into the lungs of the infant.

Common effects include improved lung compliance and reduced respiratory distress, aiding in easier breathing.

Curosurf should be handled by trained medical professionals to ensure proper administration and safety.

Yes, it is important to follow proper storage and handling guidelines and consult healthcare providers for specific precautions.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.